What Life Molecular Imaging does

Life Molecular Imaging (LMI) is a Berlin-headquartered radiopharmaceutical diagnostics company founded in 2012, specializing in PET imaging agents for neurological conditions and now operating as a wholly-owned subsidiary of Lantheus Holdings following its January 2025 acquisition for up to $750 million. The company's core asset is Neuraceq (florbetaben F-18 injection), an FDA-approved radioactive diagnostic agent that binds to amyloid plaques in the brain and is used by hospitals, imaging centers, and neurology departments to evaluate patients with cognitive impairment being assessed for Alzheimer's disease and other causes of cognitive decline. Following December 2025 FDA action, Neuraceq's label was expanded to support patient selection for amyloid-targeting therapies (e.g., lecanemab, donanemab) and to include quantitative PET imaging metrics for monitoring disease progression.

LMI's underlying technology is a proprietary F-18 labeled small molecule tracer whose 110-minute radioactive half-life mandates specialized, same-day radiopharmaceutical manufacturing and distribution logistics — a constraint the company has met by expanding manufacturing capacity, including a newly equipped Los Angeles site that delivered its first dose on August 13, 2025. Beyond its commercialized neurology asset, the company maintains pipeline programs in oncology (neuroendocrine tumors, prostate cancer), neurology, and cardiology. Revenue is generated primarily through one-time product sales of Neuraceq to healthcare providers under quote-based, radiopharmaceutical-specific procurement arrangements; pricing is not publicly disclosed.

Following the acquisition, LMI operates within Lantheus Holdings' (NASDAQ: LNTH) broader radiopharmaceutical portfolio, benefiting from the parent's established distribution infrastructure in the U.S. and broader commercial reach. The company's GTM is enterprise field-sales oriented, targeting hospitals, imaging centers, and specialist neurology decision-makers through medical conferences and direct provider engagement, with the Alzheimer's diagnostics market positioned to grow as anti-amyloid therapies achieve wider adoption.

Name

Life Molecular Imaging

Legal name

Life Molecular Imaging Ltd.

Website

https://life-mi.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

101–250 employees

Short description

Life Molecular Imaging is a Berlin-based radiopharmaceutical company (and Lantheus Holdings subsidiary) that develops and commercializes Neuraceq, an FDA-approved F-18 PET tracer for detecting amyloid plaques in patients evaluated for Alzheimer's disease and for selecting candidates for amyloid-targeting therapies.

Ownership category

akta.pro rank

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Neuraceq Product Sales: Life Molecular Imaging generates revenue through the sale of Neuraceq (florbetaben F-18 injection), an FDA-approved radioactive diagnostic agent. The product is manufactured and distributed through a specialized supply chain for use in PET imaging at hospitals and imaging centers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Life Molecular Imaging develops, manufactures, and commercializes radiopharmaceutical PET imaging agents for neurological conditions. Its flagship product, Neuraceq (florbetaben F-18 injection), is an FDA-approved radioactive diagnostic agent used to detect amyloid plaques in patients being evaluated for Alzheimer's disease and other causes of cognitive decline. The company also maintains pipeline programs in oncology, neurology, and cardiology.

Product overview

Life Molecular Imaging is a radiopharmaceutical diagnostics company focused on developing and commercializing products for neurological conditions, particularly Alzheimer's disease. The company's primary product is Neuraceq (florbetaben F-18 injection), an FDA-approved PET imaging agent for detecting amyloid plaques. Following its acquisition by Lantheus Holdings (2025), LMI operates as a subsidiary within Lantheus's portfolio of radiopharmaceutical-focused diagnostic and therapeutic products, with expanded manufacturing capabilities including Southern California production sites. The company also maintains pipeline programs in oncology (neuroendocrine tumors, prostate cancer), neurology, and cardiology.

Differentiator

Problem solved

Functional benefit

Brands

• Neuraceq: Neuraceq (florbetaben F-18 injection) is an FDA-approved radioactive diagnostic agent used to detect amyloid plaques in patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline.

Products and services

• Neuraceq (florbetaben F-18 injection) FDA-approved radioactive diagnostic PET imaging agent used to detect amyloid plaques in patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline. It supports Alzheimer's diagnosis, patient selection for amyloid-targeting therapies such as lecanemab and donanemab, and provides quantitative PET imaging metrics for monitoring disease progression. It is intended for hospitals, imaging centers, neurologists, and radiologists.

Quantifiable outcome

• The FDA expanded Neuraceq's label to include support for Alzheimer's diagnosis and patient selection for amyloid-targeting therapies
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Eli Lilly (Amyvid / florbetapir F-18): Eli Lilly markets Amyvid, a directly competing FDA-approved F-18 amyloid PET tracer for Alzheimer's imaging. Amyvid competes head-to-head with Neuraceq for the same hospital and imaging center customers for the same amyloid detection indication.
• GE HealthCare (Vizamyl / flutemetamol F-18): GE HealthCare markets Vizamyl, another FDA-approved F-18 labeled PET tracer for amyloid plaque imaging in Alzheimer's evaluation. It competes with Neuraceq on the same diagnostic question for the same neurology and imaging center customers.
• Piramal Imaging: Piramal Imaging developed and previously commercialized Neuraceq (florbetaben) prior to Life Molecular Imaging assuming commercialization. It remains a direct peer in the amyloid and neurological PET imaging agent space.
• Blue Earth Diagnostics: Blue Earth Diagnostics is a radiopharmaceutical company developing and commercializing PET imaging agents, with overlapping nuclear medicine manufacturing, distribution, and hospital-channel GTM motion similar to Life Molecular Imaging.
• Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceutical imaging agents and targeted radioligand therapies across oncology and other indications, sharing the radiopharmaceutical business model and hospital/imaging-center channel that Life Molecular Imaging operates in.

Emerging players

• Cerveau Technologies: Cerveau develops tau PET imaging ligands for Alzheimer's disease and neurodegenerative disorders, addressing a related but distinct diagnostic question from Neuraceq's amyloid imaging and partnering with pharma on therapy-selection diagnostics.

Broad incumbents

• Curium Pharma: Curium is one of the largest radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products to hospitals and imaging centers with overlapping customer base and PET/SPECT distribution footprint.
• Bracco Imaging: Bracco is a global imaging agent company offering diagnostic contrast and nuclear medicine products to hospitals and imaging centers. It is a broader incumbent in diagnostic imaging with overlapping customer relationships and distribution infrastructure.
• Lantheus Holdings (parent): Lantheus is the strategic acquirer and current parent of Life Molecular Imaging, operating the broader radiopharmaceutical portfolio including PYLARIFY (prostate cancer PET imaging). It is the most direct incumbent peer sharing manufacturing, regulatory, and commercial radiopharmaceutical infrastructure.

Others

• Siemens Healthineers (PET imaging systems): Siemens Healthineers manufactures PET/CT scanners and imaging equipment used to administer Neuraceq and other amyloid PET tracers. It is an adjacent enabling peer whose installed base directly drives demand for Neuraceq doses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Life Molecular Imaging